Evotec and Odyssey collaborate on AI-enabled R&D
Evotec and Odyssey Therapeutics have announced a strategic AI-enabled research and development (R&D) partnership to explore new treatments for autoimmune and…
Immunology
-
-
JPM26: J&J leans on immunology launches to fuel annual growth
Johnson & Johnson (J&J) expects continued growth in 2026, bolstered by recent and new product launches within the immunology space,…
-
Eli Lilly acquires inflammatory specialist Ventyx for $1.2bn
Eli Lilly has agreed to acquire autoimmune oral drug developer Ventyx Biosciences, representing the big pharma company’s latest push to…
-
Sanofi and Earendil Labs forge $2.56bn autoimmune deal
Ahead of JP Morgan 2026, pharmaceutical giant Sanofi has inked another deal with Helixon Therapeutics-affiliated startup Earendil Labs, which will…
-
CSL to pump $1.5bn into US plasma supply chain
CSL will outlay $1.5bn over the next five years in the US to grow its footprint of plasma therapy production,…
-
Elevara explores CDK4/6 inhibition for the treatment of rheumatoid arthritis
Backed by $70m in Series A funding, Elevara Medicines has launched to advance its CDK4/6 inhibitor, which belongs to a…
-
ESMO 2025: Hengrui’s immunotherapy combo shows perioperative benefit in HCC
On Saturday 19 October 2025, at the European Society for Medical Oncology (ESMO), held in Berlin, Germany, Hengrui presented results…
-
ERS 2025: Long-term CFTR use shows clinical benefit but variable microbial impact
At the 2025 European Respiratory Society (ERS) International Congress taking place in Amsterdam, the Netherlands, from 27 September to 1…
-
ERS 2025: APG808 to address need for biologic for moderate asthma
At the 2025 European Respiratory Society (ERS) International Congress takig place in Amsterdam, the Netherlands, from 27 September to 1…
-
Roche bids to broaden MS pipeline and strengthen Ocrevus influence
Roche plans to present data at a major multiple sclerosis (MS) conference indicating the continued efficacy of its investigational Bruton…
